Skip to Content
MilliporeSigma

Primaquine in vivax malaria: an update and review on management issues.

Malaria journal (2011-12-14)
Deepika Fernando, Chaturaka Rodrigo, Senaka Rajapakse
ABSTRACT

Primaquine was officially licensed as an anti-malarial drug by the FDA in 1952. It has remained the only FDA licensed drug capable of clearing the intra-hepatic schizonts and hypnozoites of Plasmodium vivax. This update and review focuses on five major aspects of primaquine use in treatment of vivax malaria, namely: a) evidence of efficacy of primaquine for its current indications; b) potential hazards of its widespread use, c) critical analysis of reported resistance against primaquine containing regimens; d) evidence for combining primaquine with artemisinins in areas of chloroquine resistance; and e) the potential for replacement of primaquine with newer drugs.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Tafenoquine succinate, ≥95% (HPLC)